CI

At a glance

ClinicalIndex Comparison Record
Phase 3Active· 30,449 enrolled
Drug / intervention
Anacetrapib +1 moredrug
Likely dose
Anacetrapib 100mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01252953
NCT01252953Phase 3Active
CompareCT.gov

REVEAL: Randomized EValuation of the Effects of Anacetrapib Through Lipid-modification. A Large-scale, Randomized Placebo-controlled Trial of the Clinical Effects of Anacetrapib Among People With Established Vascular Disease

University of Oxford·interventional·Posted Dec 3, 2010·Updated Jun 25, 2024

In Brief

A Phase 3 clinical trial evaluating Anacetrapib and Placebo anacetrapib for Atherosclerotic Cardiovascular Disease. Active but no longer recruiting, targeting 30,449 participants across 1 site.

Detailed Summary

The Randomized EValuation of the Effects of Anacetrapib Through Lipid-modification (REVEAL) trial aims to determine whether lipid modification with anacetrapib 100mg daily reduces the risk of coronary death, myocardial infarction (MI) or coronary revascularization (collectively known as major coronary events) in patients with circulatory problems who have their Low-density Lipoprotein (LDL) cholesterol level treated with a statin.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAtherosclerotic Cardiovascular Disease
CountriesUnited Kingdom
CollaboratorsMerck Sharp & Dohme LLC

Timeline

Phase 3Active
201120122013201420152016201720182019202020212022202320242025202620272028202920302031203220332034203520362037
First PostedDec 3, 2010
Enrollment StartJun 1, 2011
Primary CompletionJan 31, 2017
Study CompletionJan 31, 2037
TodayJul 2, 2026
Enrollment to primary: 5.7 yearsPosted 15.6 years ago

Interventions

Anacetrapibdrug

tablet, 100mg daily

Placebo anacetrapibdrug

tablet, 1 tablet daily